Abstract
Recent avian and swine-origin influenza virus outbreaks illustrate the ongoing threat of influenza pandemics. We investigated immunogenicity and protective efficacy of a multi-antigen (MA) universal influenza DNA vaccine consisting of HA, M2, and NP antigens in cynomolgus macaques. Following challenge with a heterologous pandemic H1N1 strain, vaccinated animals exhibited significantly lower viral loads and more rapid viral clearance when compared to unvaccinated controls. The MA DNA vaccine induced robust serum and mucosal antibody responses but these high antibody titers were not broadly neutralizing. In contrast, the vaccine induced broadly-reactive NP specific T cell responses that cross-reacted with the challenge virus and inversely correlated with lower viral loads and inflammation. These results demonstrate that a MA DNA vaccine that induces strong cross-reactive T cell responses can, independent of neutralizing antibody, mediate significant cross-protection in a nonhuman primate model and further supports development as an effective approach to induce broad protection against circulating and emerging influenza strains.
| Original language | English |
|---|---|
| Article number | e0189780 |
| Journal | PLoS ONE |
| Volume | 12 |
| Issue number | 12 |
| DOIs | |
| State | Published - Dec 2017 |
Bibliographical note
Publisher Copyright:© 2017 Koday et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding
This project has been funded by National Institutes of Health, National Institute of Allergy and Infectious Diseases (https://www.niaid.nih.gov) NIH/NIAID U01 AI074509 to DHF; NIH/NIAID, Department of Health and Human Services under Centers of Excellence in Influenza Research and Surveillance (CEIRS) (http://www.niaidceirs.org) contract HHSN272201400005C; and NIH/ORIP P51OD010425-51 to MGK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
| Funders | Funder number |
|---|---|
| National Institutes of Health (NIH) | |
| U.S. Department of Health and Human Services | |
| NIH Office of the Director | P51OD010425 |
| National Institute of Allergy and Infectious Diseases | NIH/NIAID U01 AI074509 |
| Owl Research Institute | P51OD010425-51 |
| BHF Centre of Research Excellence, Oxford | HHSN272201400005C |
ASJC Scopus subject areas
- General